AU2022235083A1 - Actrii-alk4 antagonists and methods of treating heart failure - Google Patents

Actrii-alk4 antagonists and methods of treating heart failure Download PDF

Info

Publication number
AU2022235083A1
AU2022235083A1 AU2022235083A AU2022235083A AU2022235083A1 AU 2022235083 A1 AU2022235083 A1 AU 2022235083A1 AU 2022235083 A AU2022235083 A AU 2022235083A AU 2022235083 A AU2022235083 A AU 2022235083A AU 2022235083 A1 AU2022235083 A1 AU 2022235083A1
Authority
AU
Australia
Prior art keywords
amino acid
seq
acid sequence
actriib
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022235083A
Other languages
English (en)
Inventor
Patrick Andre
Ravindra Kumar
Jia Li
Rajasekhar Naga Venkata Sai SURAGANI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of AU2022235083A1 publication Critical patent/AU2022235083A1/en
Priority to AU2025230744A priority Critical patent/AU2025230744A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2022235083A 2021-03-10 2022-03-09 Actrii-alk4 antagonists and methods of treating heart failure Abandoned AU2022235083A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025230744A AU2025230744A1 (en) 2021-03-10 2025-09-11 ActRII-ALK4 antagonists and methods of treating heart failure

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163159051P 2021-03-10 2021-03-10
US63/159,051 2021-03-10
US202163227149P 2021-07-29 2021-07-29
US63/227,149 2021-07-29
PCT/US2022/019570 WO2022192411A1 (en) 2021-03-10 2022-03-09 Actrii-alk4 antagonists and methods of treating heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025230744A Division AU2025230744A1 (en) 2021-03-10 2025-09-11 ActRII-ALK4 antagonists and methods of treating heart failure

Publications (1)

Publication Number Publication Date
AU2022235083A1 true AU2022235083A1 (en) 2023-09-21

Family

ID=83228302

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022235083A Abandoned AU2022235083A1 (en) 2021-03-10 2022-03-09 Actrii-alk4 antagonists and methods of treating heart failure
AU2025230744A Pending AU2025230744A1 (en) 2021-03-10 2025-09-11 ActRII-ALK4 antagonists and methods of treating heart failure

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025230744A Pending AU2025230744A1 (en) 2021-03-10 2025-09-11 ActRII-ALK4 antagonists and methods of treating heart failure

Country Status (9)

Country Link
US (1) US20250064952A1 (https=)
EP (1) EP4305052A4 (https=)
JP (1) JP2024511316A (https=)
KR (1) KR20230169124A (https=)
AU (2) AU2022235083A1 (https=)
BR (1) BR112023018283A2 (https=)
CA (1) CA3211507A1 (https=)
MX (1) MX2023010445A (https=)
WO (1) WO2022192411A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024336884A1 (en) * 2023-09-08 2026-03-26 35Pharma Inc. Combination therapy with actriib receptor variants and glp-1 agonists
WO2025250605A1 (en) * 2024-05-31 2025-12-04 Eli Lilly And Company Acvr2a and acvr2b rna interference agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41920B1 (fr) * 2015-04-06 2021-05-31 Acceleron Pharma Inc Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
MA41919A (fr) * 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
DK3496739T3 (da) * 2016-07-15 2021-05-10 Acceleron Pharma Inc Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
CA3039573A1 (en) * 2016-10-05 2018-04-12 Acceleron Pharma Inc. Alk4:actriib heteromultimers and uses thereof
GB201620119D0 (en) * 2016-11-29 2017-01-11 Pharmafox Therapeutics Ag Compounds
JP7669291B2 (ja) * 2019-05-30 2025-04-28 アクセレロン ファーマ インコーポレーテッド Ａｃｔｒｉｉ結合性タンパク質及びその使用
JP2023534127A (ja) * 2020-06-17 2023-08-08 アクセルロン ファーマ インコーポレイテッド ＡｃｔＲＩＩ－ＡＬＫ４アンタゴニストおよび心不全を処置する方法

Also Published As

Publication number Publication date
EP4305052A4 (en) 2025-01-01
JP2024511316A (ja) 2024-03-13
CA3211507A1 (en) 2022-09-15
US20250064952A1 (en) 2025-02-27
MX2023010445A (es) 2023-11-22
EP4305052A1 (en) 2024-01-17
WO2022192411A1 (en) 2022-09-15
KR20230169124A (ko) 2023-12-15
BR112023018283A2 (pt) 2023-10-31
AU2025230744A1 (en) 2025-10-02

Similar Documents

Publication Publication Date Title
JP7391139B2 (ja) 肺高血圧症を処置するための組成物および方法
JP7144428B2 (ja) 心不全を処置するための組成物および方法
EP4168036A1 (en) Actrii-alk4 antagonists and methods of treating heart failure
CN115989035A (zh) 用于治疗肺动脉高压(pah)的actrii蛋白
AU2025230744A1 (en) ActRII-ALK4 antagonists and methods of treating heart failure
CN116134049A (zh) 变体actriib蛋白及其用途
WO2019213442A1 (en) MULTISPECIFIC BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF
JP2024511315A (ja) Ａｃｔｒｉｉ－ａｌｋ４アンタゴニスト及び心不全の治療方法
CN117295757A (zh) ActRII-ALK4拮抗剂和治疗心力衰竭的方法
RU2857209C2 (ru) Антагонисты actrii-alk4 и способы лечения сердечной недостаточности
HK40066390A (en) Compositions comprising actriia polypeptides for use in treating pulmonary hypertension
HK40007913B (en) Compositions comprising actriia polypeptides for use in treating pulmonary hypertension
HK40007913A (en) Compositions comprising actriia polypeptides for use in treating pulmonary hypertension
HK40017995A (en) Compositions and methods for treating heart failure

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted